This correction clarifies that the alliance is to validate, not identify, breast cancer biomarkers.
NEW YORK (GenomeWeb News) — Orion Genomics will work with researchers at the Mayo Clinic to validate the company’s breast cancer screening technology in a clinical environment.
Orion will use its epigenetic biomarker-based technology with physicians at Mayo Clinic’s Department of Laboratory Medicine and Pathology to analyze cross-reactivity in more than a dozen types of breast cancer.
With epigenetic biomarkers, Orion said, it is developing tests to work in various tissues to enhance the capacity for early detection.
Its MethylScope platform can detect “methylation status of each and every human gene,” the company said, adding that it has already discovered more than 50 breast cancer biomarkers.
Orion has recently used its methylation platform to screen for colon cancer, cervical cancer, and other diseases at Washington University and at Johns Hopkins University Hospital.